health
Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.
TL;DR
- Daraxonrasib, Revolution Medicines' drug, met all primary and secondary endpoints in a Phase 3 trial for pancreatic cancer.
- Patients taking daraxonrasib lived 13.2 months on average, compared to 6.7 months for those on chemotherapy, nearly doubling survival time.
- The drug reduced the risk of death by 60% and is seen as a significant advancement for pancreatic cancer treatment.
- Daraxonrasib targets RAS mutations, which are present in about 90% of pancreatic cancer cases.
- The company plans to seek FDA approval using a National Priority Voucher for a faster review.
- Former Sen. Ben Sasse shared his positive experience with the drug, noting tumor shrinkage but also manageable side effects like a facial rash.
- The drug showed a manageable safety profile with no new concerns observed in the study.
- Revolution Medicines' stock surged over 30% following the trial results.